Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892657 · ClinicalTrials.gov registry record · Phase 4
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
A Phase 4 study of Skin Irritation, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
- 1
- Study location
NCT01892657: Completed Phase 4 study of Skin Irritation, sponsored by Galderma R&D.
NCT01892657 is a Phase 4 study of Skin Irritation that has completed, run by Galderma R&D. The registered enrollment target is 128 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01892657, a Phase 4 study of Skin Irritation, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+.
Primary Outcome
Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were
Conditions Studied
Interventions
- DRUG Facial Moisturizer with SPF 50+
Study Locations (1)
Colorado
- Thomas J. Stephens and Associates, Inc. - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
What the finished NCT01892657 record still lists
NCT01892657 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Skin Irritation appearing as the primary indexed condition, and to 1 intervention - of which Facial Moisturizer with SPF 50+ is the first listed.
NCT01892657 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01892657 about?
NCT01892657 is a clinical study titled "Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test". This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+.
What is the current status of trial NCT01892657?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2008-03. Estimated completion is 2008-08.
What conditions does trial NCT01892657 study?
This clinical trial studies the following conditions: Skin Irritation.
What interventions are being tested in trial NCT01892657?
The interventions under investigation include: Facial Moisturizer with SPF 50+ (DRUG).
Who is sponsoring clinical trial NCT01892657?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01892657 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01892657's enrollment target sits among peer trials
128 634th of 2000 higher than 1,363 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia